Russell Skibsted - Oct 1, 2025 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Financial Officer
Signature
/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Oct 1, 2025
Transactions value $
$0
Form type
4
Date filed
10/3/2025, 04:27 PM
Previous filing
Sep 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SKIBSTED RUSSELL Chief Financial Officer C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH /s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact 2025-10-02 0001308105

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 +108K $0.00 108K Oct 1, 2025 Common Stock 108K $0.00 Direct F1
transaction PCSA Stock Options (Right to Buy) Award $0 +324K $0.00 324K Oct 1, 2025 Common Stock 324K $0.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.
F2 Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.